Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer

Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2020-12, Vol.20 (1), p.1220-1220, Article 1220
Main Authors: Freytag, Morton, Kluth, Martina, Bady, Elena, Hube-Magg, Claudia, Makrypidi-Fraune, Georgia, Heinzer, Hans, Höflmayer, Doris, Weidemann, Sören, Uhlig, Ria, Huland, Hartwig, Graefen, Markus, Bernreuther, Christian, Wittmer, Corinna, Tsourlakis, Maria Christina, Minner, Sarah, Dum, David, Hinsch, Andrea, Luebke, Andreas M, Simon, Ronald, Sauter, Guido, Schlomm, Thorsten, Möller, Katharina
Format: Article
Language:English
Subjects:
Aged
Alternative splicing
Antigens
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Breast cancer
Cancer
Case-Control Studies
Cell adhesion & migration
Cytoskeleton
Deoxyribonucleic acid
DNA
DNA microarrays
DNA repair
ESRP1
ESRP2
Follow-Up Studies
Gene expression
Genetic aspects
Genomic instability
Health aspects
Humans
Immunohistochemistry
Lymph nodes
Male
Medical prognosis
Metastases
Middle Aged
Oncology, Experimental
Patients
Polyclonal antibodies
Prognosis
Prostate cancer
Prostatectomy - methods
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Proteins
Ribonucleoproteins
RNA splicing
RNA-Binding Proteins - genetics
RNA-Binding Proteins - metabolism
Survival Rate
Tissue micro array
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2) regulate alternative splicing events of various pre-mRNAs. Some of these targets play a role in cancer-associated processes, including cytoskeleton reorganization and DNA-repair processes. This study was undertaken to estimate the impact of ESRP1 and ESRP2 alterations on prostate cancer patient prognosis. A tissue microarray made from 17,747 individual cancer samples with comprehensive, pathological, clinical and molecular data was analyzed by immunohistochemistry for ESRP1 and ESRP2. Nuclear staining for ESRP1 was seen in 38.6% (36.0% low, 2.6% high) of 12,140 interpretable cancers and in 41.9% (36.4% low, 5.3% high) of 12,962 interpretable cancers for ESRP2. Nuclear protein expression was linked to advanced tumor stage, high Gleason score, presence of lymph node metastasis, early biochemical recurrence, and ERG-positive cancers (p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-020-07682-8